0001654954-24-007415.txt : 20240606 0001654954-24-007415.hdr.sgml : 20240606 20240606080040 ACCESSION NUMBER: 0001654954-24-007415 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240604 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENDRA Life Sciences Inc. CENTRAL INDEX KEY: 0001681682 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 260579295 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37969 FILM NUMBER: 241023872 BUSINESS ADDRESS: STREET 1: 3600 GREEN COURT STREET 2: SUITE 350 CITY: ANN ARBOR STATE: MI ZIP: 48105 BUSINESS PHONE: 734-335-0468 MAIL ADDRESS: STREET 1: 3600 GREEN COURT STREET 2: SUITE 350 CITY: ANN ARBOR STATE: MI ZIP: 48105 FORMER COMPANY: FORMER CONFORMED NAME: Endra Inc. DATE OF NAME CHANGE: 20160805 8-K 1 ndra_8k.htm FORM 8-K ndra_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) June 4, 2024

 

ENDRA Life Sciences Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 

 

001-37969

 

26-0579295

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3600 Green Court, Suite 350 Ann Arbor, MI

 

48105

(Address of principal executive offices)

 

(Zip Code)

 

 

 

Registrant's telephone number, including area code

 

(734) 335-0468

 

______________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

NDRA

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 1.01

Entry into a Material Definitive Agreement.

 

On June 4, 2024, ENDRA Life Sciences, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agreement”) with Craig-Hallum Capital Group LLC (the “Placement Agent”) pursuant to which the Placement Agent agreed to serve, on a best efforts basis, in connection with the issuance and sale (the “Offering”) of 6,107,691 shares of common stock and pre-funded warrants to purchase up to an aggregate of 55,430,770 shares of common stock (the “pre-funded warrants”), together with Series A warrants to purchase up to an aggregate of 61,538,461 shares of common stock (the “Series A Warrants”) and Series B warrants to purchase up to an aggregate of 61,538,461 shares of common stock (the “Series B Warrants” and, together with the Series A Warrants, the “common warrants”). The common stock, pre-funded warrants and common warrants were sold in a fixed combination, with each share of common stock or pre-funded warrant accompanied by a Series A Warrant to purchase one share of common stock and a Series B Warrant to purchase one share of common stock. In connection with the Offering, the Company also issued placement agent warrants (“Placement Agent Warrants” and, together with the pre-funded warrants and the common warrants, the “Warrants”) to purchase up to 3,076,923 shares of common stock. The Offering closed on June 5, 2024. The purchase price of each share of common stock and accompanying common warrants was $0.13 and the purchase price of each pre-funded warrant and accompanying common warrants was $0.1299.

 

The Company received gross proceeds from the Offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, of approximately $8 million.

 

The Offering was made pursuant to the Company’s registration statement on Form S-1 (File No. 333-278842), declared effective by the Securities and Exchange Commission (the “SEC” or the “Commission”) on June 4, 2024.

 

The common warrants become exercisable only upon the later of (i) receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (the “Warrant Stockholder Approval”) and (ii) the first trading day following effectiveness of an amendment to the Company’s certificate of incorporation (the “Charter Amendment”) to increase the number of authorized shares of common stock in an amount sufficient to provide for issuance of all shares of common stock underlying the common warrants (the “Initial Exercise Date”). Each Series A Warrant has an exercise price of $0.22 per share of common stock and will expire five years from the Initial Exercise Date. Each Series B Warrant has an exercise price of $0.22 per share of common stock and will expire two and one-half years from the Initial Exercise Date.

 

Pursuant to the common warrants, the Company shall hold a special meeting of stockholders to obtain the Warrant Stockholder Approval and approval of the Charter Amendment no later than 75 days after the closing of the Offering. In the event that the Company is unable to obtain the Warrant Stockholder Approval, the Series Warrants will not be exercisable and therefore will have no value.

 

Under the alternate cashless exercise option of the Series B Warrants, the holder of a Series B Warrant has the right to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cashless exercise of the Series B Warrant using $0.001 as the exercise price for that purpose and (y) 3.0. In addition, the common warrants include a provision that resets their respective exercise prices in the event of a reverse split of the Company’s common stock to a price equal to the lesser of (i) the then current exercise price and (ii) lowest volume weighted average price (VWAP) during the period commencing five trading days immediately preceding and the five trading days commencing on the date the Company effects a reverse stock split with a proportionate adjustment to the number of shares underlying the Series A Warrants and Series B Warrants.

 

Subject to certain exceptions, the Series A Warrants provide for an adjustment to the exercise price and number of shares underlying the Series A Warrants upon the Company’s issuance of Common Stock or Common Stock equivalents at a price per share that is less than the exercise price of the Series A Warrants.

 

A holder does not have the right to exercise any portion of the Series A Warrants or Series B Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series A Warrants and Series B Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following notice from the holder to us.

 

 
2

 

 

The Company offered to each purchaser whose purchase of shares of common stock in this offering would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of the Company’s outstanding common stock immediately following the consummation of the Offering, the opportunity to purchase pre-funded warrants. Subject to limited exceptions, a holder of pre-funded warrants does not have the right to exercise any portion of its pre-funded warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each pre-funded warrant is exercisable for one share of common stock. For each pre-funded warrant the Company sold, the number of shares of common stock that the Company offered was decreased on a one-for-one basis.

 

The Placement Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. In connection with this Offering, under the Placement Agreement, the Company and each of its directors and officers agreed to be subject to a lock-up period of 90 days following the date of closing of the Offering (the “Company Lockup Period”). During the Company Lockup Period, the Company and such persons may not offer, sell, contract to sell or otherwise dispose of or hedge Common Stock or securities convertible into or exchangeable for Common Stock, subject to customary exceptions. The Placement Agent may, in its sole discretion and without notice, waive the terms of the Company Lockup Period.

 

Pursuant to the Placement Agreement, the Company paid the Placement Agents a cash placement fee equal to 7.0% of the aggregate gross proceeds raised in the Offering. The Company reimbursed expenses of the Placement Agent in connection with the Offering, including but not limited to legal fees, of $100,000. The Company also issued to the Placement Agent and its designees Placement Agent Warrants to purchase up to 3,076,923 shares of common stock (which equals 5.0% of the number of shares of common stock and pre-funded warrants sold in the Offering) on similar terms as the common warrants, except that the Placement Agent Warrants have an expiration date of three and one-half years from the Initial Exercise Date and were immediately exercisable upon issuance.

 

The Company has agreed to indemnify the Placement Agents against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”), or to contribute to payments that the Placement Agents may be required to make in respect of those liabilities.

 

The Company has agreed, subject to certain exceptions, not to effect any issuance of Common Stock or securities convertible into Common Stock involving a Variable Rate Transaction, as defined in the Placement Agreement, for a period commencing on the date of the Placement Agreement until 180 days following the closing of the Offering.

 

The foregoing descriptions of the terms and conditions of the forms of Placement Agreement, Placement Agent Warrant, Series A Warrant, Series B Warrant and the Pre-Funded Warrant are qualified in their entirety by reference to the full text of such documents, which are attached to this Current Report on Form 8-K as Exhibits 10.1, 4.1, 4.2, 4.3 and 4.4, respectively, and are incorporated herein by reference in their entirety.

 

This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be sold in any state or jurisdiction in which this offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

 

Item 7.01

Regulation FD Disclosure.

 

On June 4, 2024, the Company issued a press release announcing the pricing of the Offering. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 
3

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

 

 

 

4.1

 

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1 filed on May 10, 2024)

4.2

 

Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1 filed on May 31, 2024)

4.3

 

Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1 filed on May 31, 2024)

4.4

 

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form S-1 filed on May 10, 2024)

10.1

 

Form of Placement Agency Agreement by and between ENDRA Life Sciences, Inc. and Craig-Hallum Capital Group LLC (incorporated by reference to Exhibit 10.23 to the Company’s Registration Statement on Form S-1 filed on May 10, 2024)

99.1

Press Release dated June 4, 2024, furnished herewith.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
4

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ENDRA Life Sciences Inc.

 

June 6, 2024

 

 

 

By:

/s/ Francois Michelon

 

 

Name:

Francois Michelon

 

 

Title:

President and Chief Executive Officer

 

 

 
5

 

 

 EX-99.1 2 ndra_ex991.htm EX-99.1 ndra_ex991.htm

 

EXHIBIT 99.1 

 

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

 

ANN ARBOR, Mich. (June 4, 2024) – ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.

 

The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”). The Warrants cannot be exercised until the later of the approval of their terms by the Company’s stockholders at a stockholders’ meeting and effectiveness of an amendment to the Company’s certificate of incorporation increasing the number of authorized shares of its common stock. The Series A Warrants will expire on the five-year anniversary of the initial exercise date and the Series B Warrants will expire on the two and one-half-year anniversary of the initial exercise date.

 

The purchase price of each share of common stock and accompanying Warrants is $0.13 and the purchase price of each pre-funded warrant and accompanying Warrants will be equal to such price minus $0.0001.

 

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. This offering is expected to close on or about June 5, 2024, subject to satisfaction of customary closing conditions.

 

Craig-Hallum is acting as sole placement agent for the offering.

 

The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-278842) previously filed and declared effective by the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a written preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Alternatively, when available, copies of the final prospectus relating to this offering may be obtained from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, by telephone at (612) 334-6300 or by email at prospectus@chlm.com.

 

About ENDRA Life Sciences Inc.

 

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology that characterizes tissue similar to an MRI, but at 1/40th the cost and at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS ® is initially focused on the non-invasive assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including non-invasive visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

 

 

 

 

Forward-Looking Statements

 

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: statements regarding the expected closing of the public offering, the amount of proceeds from the public offering and the intended use of proceeds from the offering; estimates of the timing of future events and anticipated results of our development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: market and other general economic conditions, which may impact whether we consummate the public offering; whether we will be able to satisfy the conditions required to close any sale of securities in the proposed offering; the fact our management will have broad discretion in the use of the proceeds from any sale of the securities in the proposed offering; the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA’s ability to maintain compliance with Nasdaq listing standards; ENDRA’s dependence on its senior management team; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and the Risk Factors sections of the preliminary prospectus describing the terms of the proposed offering filed with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

 

Company Contact:

Irina Pestrikova

Senior Director, Finance

investors@endrainc.com

www.endrainc.com

 

Investor Relations Contact:

Yvonne Briggs

LHA Investor Relations

(310) 691-7100

ybriggs@lhai.com

 

 

 

 EX-101.SCH 3 ndra-20240604.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ndra-20240604_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 5 ndra-20240604_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 ndra-20240604_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 ndra-20240604_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 04, 2024
Cover [Abstract]  
Entity Registrant Name ENDRA Life Sciences Inc.
Entity Central Index Key 0001681682
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jun. 04, 2024
Entity File Number 001-37969
Entity Incorporation State Country Code DE
Entity Tax Identification Number 26-0579295
Entity Address Address Line 1 3600 Green Court
Entity Address Address Line 2 Suite 350
Entity Address City Or Town Ann Arbor
Entity Address State Or Province MI
Entity Address Postal Zip Code 48105
City Area Code 734
Local Phone Number 335-0468
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol NDRA
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9 MNMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MT MFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5 MRMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"% M'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:P MIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( M !- QE@D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_ M[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ M0=@S9)[NF:*'3^ 5!+ P04 M " 30,9899!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RM MDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C> MO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0 MP1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH% M.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D M(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S6 M3AI_YHOA/UY_ 5!+ 0(4 Q0 ( !- QE@'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ $T#&6,<8 M VGN *P( !$ ( !KP &1O8U!R;W!S+V-O&UL M4$L! A0#% @ $T#&6)E&PO=V]R:W-H965T&UL M4$L! A0#% @ $T#&6)^@&_"Q @ X@P T ( !DPP M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M A0#% @ $T#&6"0>FZ*M ^ $ !H ( !N!$ 'AL M+U]R96QS+W=O9(9 M 0 SP, !, ( !G1( %M#;VYT96YT7U1Y<&5S72YX;6Q0 52P4& D "0 ^ @ YQ, end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://ndra.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ndra-20240604.xsd ndra-20240604_cal.xml ndra-20240604_def.xml ndra-20240604_lab.xml ndra-20240604_pre.xml ndra_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ndra_8k.htm": { "nsprefix": "ndra", "nsuri": "http://ndra.com/20240604", "dts": { "schema": { "local": [ "ndra-20240604.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ndra-20240604_cal.xml" ] }, "definitionLink": { "local": [ "ndra-20240604_def.xml" ] }, "labelLink": { "local": [ "ndra-20240604_lab.xml" ] }, "presentationLink": { "local": [ "ndra-20240604_pre.xml" ] }, "inline": { "local": [ "ndra_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://ndra.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-06-04to2024-06-04", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ndra_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-06-04to2024-06-04", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ndra_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ndra.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001654954-24-007415-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-24-007415-xbrl.zip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end XML 19 ndra_8k_htm.xml IDEA: XBRL DOCUMENT 0001681682 2024-06-04 2024-06-04 iso4217:USD shares iso4217:USD shares 0001681682 false 8-K 2024-06-04 ENDRA Life Sciences Inc. DE 001-37969 26-0579295 3600 Green Court Suite 350 Ann Arbor MI 48105 734 335-0468 false false false false Common stock, par value $0.0001 per share NDRA NASDAQ false